(Q36566726)

15 August 2017

1 reference

title

Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? (English)

1 reference

15 August 2017

Zaccara G

1

1 reference

15 August 2017

Messori A

series ordinal

2

1 reference

15 August 2017

Cincotta M

series ordinal

3

1 reference

15 August 2017

Burchini G

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Acta Neurologica Scandinavica

15 August 2017

published in

1 reference

15 August 2017

volume

114

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

157-168

1 reference

Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Long-term continuation of levetiracetam in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. The Steps Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Long-term study with gabapentin in patients with drug-resistant epileptic seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Levetiracetam in clinical use--a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Levetiracetam in refractory epilepsy: a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

A prospective analysis of the outcome of levetiracetam in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

The long term retention of levetiracetam in a large cohort of patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Blood and plasma viscosity and microvascular function in hemodilution. A perspective from La Jolla, California

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Topiramate in the long-term management of refractory epilepsy. Topiramate YOL Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Revisiting the concept of identifiable neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

The Long-Term Use of Gabapentin, Lamotrigine, and Vigabatrin in Patients with Chronic Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

An Audit of the Perceived Efficacy and Tolerability of Gabapentin Therapy in an Out-Patient Cohort with Chronic Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00705.X

Oxcarbazepine add-on for drug-resistant partial epilepsy

21 January 2018

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002028

Identifiers

DOI

10.1111/J.1600-0404.2006.00705.X

1 reference

15 August 2017

1 reference